Movement disorder is a neurological condition characterized by unusual or abnormal movements of the body. People with movement disorder may have difficulty walking, talking, and performing other basic tasks. The cause of movement disorders can be varied. It can be caused by changes in brain functioning, diseases such as Parkinson’s, Huntington’s, dystonia, etc., or drug side effects. The basic symptoms of movement disorders are involuntary movements, impaired muscle control, diminished coordination and balance. People with movement disorder may also experience stiffness, tremors, muscle spasms, and difficulty with regular activities. Movement disorder can be diagnosed by a physical and neurological examination along with imaging techniques like X-ray, CT scan, MRI, and ultrasound. Other tests may include pharmaceutical challenge tests, genetic tests, and neuropsychological tests. Treatment of movement disorders depends on the underlying cause. In some cases, medications such as anticholinergics, anti-seizure drugs, and dopamine agonists can be used to control symptoms. Surgery may also be used to correct abnormalities in the area affected by the disorder. In addition, physical therapy, occupational therapy, and speech therapy can also be used to maintain or improve functioning. Living with a movement disorder can be very difficult and often disrupts daily activities. Along with treatments for the movement disorder, it is important to also have support from family and friends. Supportive care can be beneficial in helping a person cope with the difficulties of living with such a disorder. Additionally, proper rest, exercise, and a healthy diet can help a person manage the symptoms of movement disorder.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States